An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With Hypertriglyceridemia
Phase of Trial: Phase II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs Tipelukast (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Proof of concept; Therapeutic Use
- Sponsors MediciNova
- 10 Aug 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
- 10 Aug 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Dec 2017.
- 14 Jul 2016 Planned number of patients changed from 20 to 40.